TXMD · TherapeuticsMD, Inc.

0001213900-26-036515

Summary

TherapeuticsMD narrowed its operating loss through cost discipline and royalty efficiencies from licensed products, generating positive operating cash flow while achieving revenue from Mayne Pharma partnership, though net losses persist amid liquidity needs for ongoing operations.

Key takeaways

Revenue was $3.0M, reflecting increase in sales from licensed products and increased efficiencies realized as a royalty-based business.
Net income was -$569.0K.
Diluted EPS was $-0.05.

Full analysis

TherapeuticsMD's 2025 financial results reflect progress in its royalty-based model with Mayne Pharma, where revenue of $3.0 million stemmed from licensed product sales and operational efficiencies. This revenue recognition aligns with non-refundable up-front fees transferred upon granting rights to functional intellectual property, reducing reliance on direct manufacturing and sales.